Bio View (XTAE:BIOV) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Bio View ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bio View's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Bio View ROCE % Historical Data

The historical data trend for Bio View's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio View ROCE % Chart

Bio View Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

13.51

4.47

10.10

3.49

3.57

Bio View Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-5.76	9.82	16.47	-	-

Bio View ROCE % Calculation

Bio View's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	1.108	/	( ( (41.928 - 9.875)	+	(41.955 - 11.909) )	/ 2 )
	=	1.108	/	( (32.053	+	30.046)	/ 2 )
	=	1.108	/	31.0495
	=	3.57 %

Bio View's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	0	/	( ( (42.546 - 10.14)	+	(41.955 - 11.909) )	/ 2 )
	=	0	/	( ( 32.406	+	30.046 )	/ 2 )
	=	0	/	31.226
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Bio View (XTAE:BIOV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bio View ROCE % Related Terms

Thank you for viewing the detailed overview of Bio View's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio View (XTAE:BIOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Pekeris Street, Rehovot, ISR, 7670203

Website

http://www.bioview.co.il

Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View (XTAE:BIOV) Headlines

No Headlines